Safety of a mRNA COVID-19 Vaccine in Patients with Indolent Systemic Mastocytosis

Authors

  • Joana Gouveia Serviço de Imunoalergologia. Centro Hospitalar Universitário de Santo António. Porto.
  • Maria Alexandra Rodrigues Serviço de Dermatologia. Centro Hospitalar Universitário de Santo António. Porto.
  • Iolanda Fernandes Serviço de Dermatologia. Centro Hospitalar Universitário de Santo António. Porto; Consulta Multidisciplinar de Linfomas Cutâneos e Mastocitoses. Centro Hospitalar Universitário de Santo António. Porto; Unidade Multidisciplinar de Investigação Biomédica. Instituto de Ciências Biomédicas Abel Salazar. Universidade do Porto. Porto.
  • Renata Cabral Serviço de Imunoalergologia. Centro Hospitalar Universitário de Santo António. Porto.
  • Helena Falcão Serviço de Imunoalergologia. Centro Hospitalar Universitário de Santo António. Porto.

DOI:

https://doi.org/10.20344/amp.20851

Keywords:

COVID-19/immunology, COVID-19 Vaccines, Mastocytosis, Systemic/immunology, RNA, Messenger

Abstract

N/a.

Downloads

Download data is not yet available.

References

Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am. 2014;34:283-95.

Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA. 2021;325:780.

Rama TA, Moreira A, Castells M. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis. J Allergy Clin Immunol. 2021;147:877-8.

Giannetti MP, Olivieri F, Godwin G, Weller E, Nicoloro-SantaBarbara J, Bonadonna P, et al. Outcomes of COVID-19 vaccination in 323 patients with clonal and non-clonal mast cell activation disorders. Allergy. 2023;78:301-4.

Kaakati R, Khokhar D, Akin C. Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome. J Allergy Clin Immunol Pract. 2021;9:3198-9.

Downloads

Published

2024-03-01

How to Cite

1.
Gouveia J, Rodrigues MA, Fernandes I, Cabral R, Falcão H. Safety of a mRNA COVID-19 Vaccine in Patients with Indolent Systemic Mastocytosis. Acta Med Port [Internet]. 2024 Mar. 1 [cited 2024 May 18];37(3):224-5. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/20851

Issue

Section

Letters to the Editor